A deep report two days later reconstructed the scene on the day results were announced: all 4,500 Moderna employees gathered temporarily in the company cafeteria, waiting for management to announce a result a decade in the making. CEO Stephane Bancel even spoke from note cards; some embraced and wept, and champagne was opened on site. For Moderna, this was not only a clinical breakthrough but also the pivotal moment a long bet had finally reached.
The COVID vaccine once brought Moderna about $36 billion in sales within a few short years, providing ample cash to keep betting on high-risk projects such as cancer. But as the pandemic dividend faded, the company went through sales crashes, layoffs, R&D cuts and a sharp stock decline, and the market began to question what it could grow on after the COVID era. Now, Moderna has finally awaited a weighty answer.
Whether the efficacy can be sustained, whether personalized vaccines can be produced at scale, whether costs can be accepted by the market, and whether the technology can be replicated across more cancer types will determine whether this breakthrough is a brief rebound or Moderna truly opening a second growth curve.
Moderna began researching mRNA cancer therapies early, but did not focus on oncology in its early days. It was not until 2013, when hedge-fund manager Patrick DeGolier, whose wife had died of lung cancer, decided to invest $500,000 in Moderna's oncology program, that the company further advanced this direction. What truly changed the project's fate was the 2016 partnership with Merck. At the time, Merck invested $200 million, and the two sides began exploring the effect of combining an mRNA cancer vaccine with Keytruda. This funding, together with the combination with a mature cancer immunotherapy, provided important support for the project's continued advancement.
Even if clinical results keep improving, Moderna must face another, more practical question: can this vaccine actually become a good business? Personalized treatment means each patient may need a vaccine redesigned based on their own tumor mutations. Compared with traditional drugs that can be mass-produced, this model is naturally more complex and implies higher manufacturing and supply-chain costs. Experts note that such personalized therapies may face high treatment costs in the future. This means the challenge Moderna faces in the next stage is not just "can it cure," but also whether it can be mass-produced, whether insurance will cover it, and whether patients can afford it.
Currently, Moderna and Merck plan to further disclose relevant clinical data and push such therapies beyond melanoma into lung cancer, kidney cancer and pancreatic cancer. If subsequent trials continue to validate efficacy, then Moderna's decade-plus gamble may finally have reached the critical stage of payoff. For a company that once soared on COVID vaccines and then fell into a trough as the pandemic receded, what truly deserves attention is not how much the stock rose in a day, but whether it can prove through the cancer vaccine that the mRNA story may have only just begun.
